Literature DB >> 25019210

High-grade cervical lesions among women attending a reference clinic in Brazil: associated factors and comparison among screening methods.

Neide T Boldrini1, Luciana B Freitas1, Amanda R Coutinho1, Flavia Z Loureiro1, Liliana C Spano1, Angélica E Miranda1.   

Abstract

BACKGROUND: Although screening for cervical cancer is recommended for women in most countries, the incidence of cervical cancer is greater in developing countries. Our goal was to determine the prevalence and factors associated with high-grade lesions/cervical cancer among women attending a reference clinic in Brazil and evaluate the correlation of histology with cytology, colposcopy and the high-risk HPV (HR-HPV) tests.
METHODS: A cross-sectional study of women attending a colposcopy clinic was carried out. The patients were interviewed to collect demographic, epidemiological and clinical data. Specimens were collected for cervical cytology, Chlamydia trachomatis and HPV testing using the Hybrid Capture (HC) and PCR tests. Colposcopy was performed for all patients and biopsy for histology when cell abnormalities or cervical intraepithelial neoplasia (CIN) were present.
RESULTS: A total of 291 women participated in the study. The median age was 38 years (DIQ: 30-48 years). The prevalence of histologically confirmed high-grade lesions/cervical cancer was 18.2% (95%, CI: 13.8%-22.6%), with 48 (16.5%) cases of CIN-2/CIN-3 and 5 (1.7%) cases of invasive carcinoma. In the final logistic regression model, for ages between 30 and 49 years old [OR = 4.4 (95%: 1.01-19.04), history of smoking [OR = 2.4 (95%, CI: 1.14-5.18)], practice of anal intercourse [OR = 2.4 (95%, CI: 1.10-5.03)] and having positive HC test for HR-HPV [OR = 11.23 (95%, CI: 4 0.79-26, 36)] remained independently associated with high-grade lesions/cervical cancer. A total of 64.7% of the cases CIN-3\Ca in situ were related to HPV-16. Non-oncogenic HPV were only found in CIN-1 biopsy results. Compared to histology, the sensitivity of cytology was 31.8%, the specificity 95.5%; the sensitivity of colposcopy for high-grade lesions/cervical cancer was 51.0%, specificity was 91.4% and the concordance with HPV testing was high.
CONCLUSIONS: The results confirm an association of HR-HPV with precursor lesions for cervical cancer. These data emphasize that cytological screening to detect precursor lesions is still important in some regions and that HR-HPV should be included for screening.

Entities:  

Mesh:

Year:  2014        PMID: 25019210      PMCID: PMC4094527          DOI: 10.1371/journal.pone.0102169

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  33 in total

1.  Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening.

Authors:  Freddie Bray; Anja H Loos; Peter McCarron; Elizabete Weiderpass; Mark Arbyn; Henrik Møller; Matti Hakama; D Max Parkin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-03       Impact factor: 4.254

Review 2.  Clinical utility of HPV genotyping.

Authors:  Chris J Meijer; Peter J Snijders; Philip E Castle
Journal:  Gynecol Oncol       Date:  2006-08-24       Impact factor: 5.482

3.  Human papillomavirus infection in Rio de Janeiro, Brazil: a retrospective study.

Authors:  M O O Carvalho; F N Carestiato; P H Perdigão; M P P T Xavier; Kc Silva; M O Botelho; L H S Oliveira; S M B Cavalcanti
Journal:  Braz J Infect Dis       Date:  2006-01-06       Impact factor: 1.949

4.  [Performance by cytology and hybrid capture II in screening for high-grade squamous intraepithelial lesions in women with HIV].

Authors:  Letícia Martins Raposo; Luciane Velasque; Paula Mendes Luz; Ruth Khalili Friedman; Andrea Cytryn; Angela Cristina Vasconcelos de Andrade; Tazio Vanni; Pedro E A A Brasil; Fabio Russomano; Valdiléa Gonçalves Veloso; Beatriz Grinsztejn; Claudio José Struchiner
Journal:  Cad Saude Publica       Date:  2011-07       Impact factor: 1.632

5.  Accuracy of Papanicolaou test among HIV-infected women.

Authors:  Jean R Anderson; Pangaja Paramsothy; Charles Heilig; Denise J Jamieson; Keerti Shah; Ann Duerr
Journal:  Clin Infect Dis       Date:  2006-01-13       Impact factor: 9.079

6.  International trends in incidence of cervical cancer: II. Squamous-cell carcinoma.

Authors:  A P Vizcaino; V Moreno; F X Bosch; N Muñoz; X M Barros-Dios; J Borras; D M Parkin
Journal:  Int J Cancer       Date:  2000-05-01       Impact factor: 7.396

7.  Prevalence of cervical intraepithelial neoplasia grades II/III and cervical cancer in patients with cytological diagnosis of atypical squamous cells when high-grade intraepithelial lesions (ASC-H) cannot be ruled out.

Authors:  Andréa Cytryn; Fábio Bastos Russomano; Maria José de Camargo; Lucília Maria Gama Zardo; Nilza Maria Sobral Rebelo Horta; Rachel de Carvalho Silveira de Paula Fonseca; Maria Aparecida Tristão; Aparecida Cristina Sampaio Monteiro
Journal:  Sao Paulo Med J       Date:  2009-09       Impact factor: 1.044

8.  Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study.

Authors:  Susanne K Kjaer; Adriaan J C van den Brule; Gerson Paull; Edith I Svare; Mark E Sherman; Birthe L Thomsen; Mette Suntum; Johannes E Bock; Paul A Poll; Chris J L M Meijer
Journal:  BMJ       Date:  2002-09-14

9.  European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.

Authors:  J Jordan; M Arbyn; P Martin-Hirsch; U Schenck; J-J Baldauf; D Da Silva; A Anttila; P Nieminen; W Prendiville
Journal:  Cytopathology       Date:  2008-12       Impact factor: 2.073

10.  A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment.

Authors:  Anthony S Gunnell; Nathalie Ylitalo; Sven Sandin; Pär Sparén; H-O Adami; Samuli Ripatti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

View more
  5 in total

1.  Anal human papillomavirus (HPV) prevalences and factors associated with abnormal anal cytology in HIV-infected women in an urban cohort from Rio de Janeiro, Brazil.

Authors:  Mary C Cambou; Paula M Luz; Jordan E Lake; José Eduardo Levi; José Ricardo Coutinho; Angela de Andrade; Thais Heinke; Mônica Derrico; Valdilea G Veloso; Ruth K Friedman; Beatriz Grinsztejn
Journal:  AIDS Patient Care STDS       Date:  2015-01       Impact factor: 5.078

2.  Elevated glucose-6-phosphate dehydrogenase expression in the cervical cancer cases is associated with the cancerigenic event of high-risk human papillomaviruses.

Authors:  Tao Hu; Ya-Shan Li; Bo Chen; Ye-Fei Chang; Guang-Cai Liu; Ying Hong; Hong-Lan Chen; Yan-Bin Xiyang
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-23

3.  A cross-sectional study of high-risk human papillomavirus clustering and cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil.

Authors:  Jessica L Castilho; José Eduardo Levi; Paula M Luz; Mary Catherine Cambou; Tazio Vanni; Angela de Andrade; Mônica Derrico; Valdiléa G Veloso; Beatriz Grinsztejn; Ruth K Friedman
Journal:  BMC Cancer       Date:  2015-06-23       Impact factor: 4.430

4.  Sexually transmitted infections among women living with HIV in a Brazilian city.

Authors:  Neide Aparecida Tosato Boldrini; Lays Paula Bondi Volpini; Luciana Bueno Freitas; Liliana Cruz Spano; Carlos Musso; Maria Carmen Lopes Ferreira Silva Santos; Helena Lucia Barroso Dos Reis; Angelica Espinosa Miranda
Journal:  Braz J Infect Dis       Date:  2021-01-06       Impact factor: 3.257

5.  Hybrid capture as a tool for cervical lesions screening in HIV-infected women: insights from a Brazilian cohort.

Authors:  Emilia Moreira Jalil; Paula M Luz; Marcel Quintana; Ruth Khalili Friedman; Rosa M Domingues S Madeira; Angela Cristina Andrade; Janice Chicarino; Ronaldo Ismerio Moreira; Monica Derrico; José Eduardo Levi; Fabio Russomano; Valdilea Gonçalves Veloso; Beatriz Grinsztejn
Journal:  Braz J Infect Dis       Date:  2017-12-06       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.